BioLineRx Current Ratio 2012-2019 | BLRX

BioLineRx current ratio from 2012 to 2019. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
BioLineRx Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2019-03-31 $0.04B $0.01B 5.12
2018-12-31 $0.03B $0.01B 4.74
2018-09-30 $0.04B $0.01B 7.53
2018-06-30 $0.04B $0.01B 8.02
2018-03-31 $0.05B $0.01B 7.37
2017-12-31 $0.05B $0.01B 7.49
2017-09-30 $0.06B $0.01B 10.11
2017-06-30 $0.05B $0.01B 9.91
2017-03-31 $0.03B $0.01B 6.12
2016-12-31 $0.04B $0.00B 9.86
2016-09-30 $0.04B $0.00B 11.71
2016-06-30 $0.04B $0.00B 15.22
2016-03-31 $0.05B $0.00B 17.93
2015-12-31 $0.05B $0.00B 15.35
2015-09-30 $0.05B $0.00B 14.45
2015-06-30 $0.06B $0.00B 13.42
2015-03-31 $0.06B $0.00B 14.11
2014-12-31 $0.04B $0.00B 12.12
2014-09-30 $0.03B $0.00B 11.47
2014-06-30 $0.03B $0.00B 12.35
2014-03-31 $0.04B $0.00B 11.87
2013-12-31 $0.02B $0.00B 6.17
2013-09-30 $0.02B $0.00B 4.74
2013-06-30 $0.02B $0.01B 4.50
2013-03-31 $0.03B $0.01B 3.89
2012-12-31 $0.02B $0.01B 3.45
2012-09-30 $0.03B $0.01B 3.91
2012-06-30 $0.03B $0.01B 4.85
2012-03-31 $0.04B $0.01B 5.02
2011-12-31 $0.03B $0.01B 4.02
2011-09-30 $0.03B $0.01B 4.63
2011-06-30 $0.04B $0.01B 5.12
2011-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.035B $0.000B
Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $54.361B 34.73
Astellas Pharma (ALPMY) Japan $28.294B 13.87
Takeda Pharmaceutical (TAK) Japan $28.107B 8.25
Eisai (ESALY) Japan $16.062B 27.62
UCB SA (UCBJF) Belgium $15.866B 0.00
Grifols, S.A (GRFS) Spain $14.831B 18.76
Merck (MKGAF) Germany $13.435B 18.33
IPSEN SA ADR (IPSEY) France $10.783B 0.00
Sage Therapeutics (SAGE) United States $9.586B 0.00
Ionis Pharmaceuticals (IONS) United States $9.522B 20.82
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Neurocrine Biosciences (NBIX) United States $7.992B 0.00
Catalent (CTLT) United States $7.866B 31.57
Jazz Pharmaceuticals (JAZZ) Ireland $7.641B 10.48
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 19.83
Nektar Therapeutics (NKTR) United States $5.789B 9.43
STADA ARZNEIMI (STDAF) Germany $5.634B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.420B 0.00
Orion OYJ (ORINY) Finland $5.275B 24.34
Hypermarcas (HYPMY) Brazil $4.894B 17.20
Evotec AG (EVTCY) Germany $4.308B 46.24
Tilray (TLRY) Canada $4.300B 0.00
FibroGen (FGEN) United States $4.000B 0.00
United Therapeutics (UTHR) United States $3.338B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.172B 11.39
Arrowhead Pharmaceuticals (ARWR) United States $2.636B 397.14
PTC Therapeutics (PTCT) United States $2.549B 0.00
Xencor (XNCR) United States $2.481B 67.72
Zogenix (ZGNX) United States $2.005B 0.00
Portola Pharmaceuticals (PTLA) United States $1.776B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.687B 81.72
Enanta Pharmaceuticals (ENTA) United States $1.609B 21.99
Ironwood Pharmaceuticals (IRWD) United States $1.607B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.577B 0.00
Heron Therapeutics (HRTX) United States $1.448B 0.00
USANA Health Sciences (USNA) United States $1.388B 12.06
Corcept Therapeutics (CORT) United States $1.223B 17.46
ArQule (ARQL) United States $1.162B 0.00
Aerie Pharmaceuticals (AERI) United States $1.159B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.048B 3.77
Radius Health (RDUS) United States $1.014B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.983B 0.00
Endo (ENDP) Ireland $0.893B 1.44
Spectrum Pharmaceuticals (SPPI) United States $0.887B 0.00
Concordia (CXRXF) Canada $0.719B 0.00
Aptorum Group (APM) China $0.673B 0.00
Organogenesis Holdings (ORGO) United States $0.623B 0.00
TherapeuticsMD (TXMD) United States $0.598B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.583B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.580B 0.00
GlycoMimetics (GLYC) United States $0.555B 0.00
Karyopharm Therapeutics (KPTI) United States $0.511B 0.00
Akebia Therapeutics (AKBA) United States $0.503B 0.00
Translate Bio (TBIO) United States $0.499B 0.00
ChemoCentryx (CCXI) United States $0.479B 0.00
Siga Technologies (SIGA) United States $0.469B 1.11
Dermira (DERM) United States $0.462B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.460B 23.19
Dova Pharmaceuticals (DOVA) United States $0.453B 0.00
Flexion Therapeutics (FLXN) United States $0.435B 0.00
CannTrust Holdings (CTST) Canada $0.432B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.422B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.420B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.420B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.407B 0.00
CV Sciences (CVSI) United States $0.405B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.397B 0.00
Indivior (INVVY) United States $0.393B 1.42
Collegium Pharmaceutical (COLL) United States $0.375B 0.00
ImmunoGen (IMGN) United States $0.371B 0.00
Innate Pharma SA (IPHYF) France $0.369B 0.00
Harpoon Therapeutics (HARP) United States $0.366B 0.00
Xeris Pharmaceuticals (XERS) United States $0.322B 0.00
OptiNose (OPTN) United States $0.304B 0.00
Rafael Holdings (RFL) United States $0.299B 0.00
KalVista Pharmaceuticals (KALV) United States $0.293B 0.00
Concert Pharmaceuticals (CNCE) United States $0.272B 0.00
Molecular Templates (MTEM) United States $0.264B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.250B 0.00
Aratana Therapeutics (PETX) United States $0.248B 0.00
Lannett Co Inc (LCI) United States $0.229B 2.23
Ocular Therapeutix (OCUL) United States $0.227B 0.00
Recro Pharma (REPH) United States $0.225B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.224B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.211B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.174B 0.00
Calithera Biosciences (CALA) United States $0.174B 0.00
Redhill Biopharma (RDHL) Israel $0.173B 0.00
IMV INC (IMV) Canada $0.170B 0.00
Nature's Sunshine Products (NATR) United States $0.167B 54.00
Taiwan Liposome (TLC) Taiwan $0.164B 0.00
Ardelyx (ARDX) United States $0.159B 0.00
MEI Pharma (MEIP) United States $0.150B 0.00
Jounce Therapeutics (JNCE) United States $0.141B 0.00
Majesco Entertainment (PTE) United States $0.141B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.139B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.124B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.122B 0.00
AgeX Therapeutics (AGE) United States $0.113B 0.00
DURECT (DRRX) United States $0.111B 0.00
Champions Oncology (CSBR) United States $0.104B 0.00
Aquestive Therapeutics (AQST) United States $0.104B 0.00
Generex Biotechnology (GNBT) United States $0.099B 0.00
Infinity Pharmaceuticals (INFI) United States $0.096B 0.00
Capnia (SLNO) United States $0.095B 0.00
RENEURON GP (RNUGF) United Kingdom $0.094B 0.00
Mast Therapeutics (SVRA) United States $0.094B 0.00
Iterum Therapeutics (ITRM) Ireland $0.094B 0.00
Genocea Biosciences (GNCA) United States $0.093B 0.00
Aclaris Therapeutics (ACRS) United States $0.092B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.089B 63.89
MediWound (MDWD) Israel $0.085B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.084B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.083B 0.00
Natural Alternatives (NAII) United States $0.083B 8.27
Avadel Pharmaceuticals (AVDL) Ireland $0.082B 0.00
Cardiome Pharma (CORV) Canada $0.080B 0.00
Nivalis Therapeutics (ALPN) United States $0.078B 0.00
Otonomy (OTIC) United States $0.077B 0.00
China SXT Pharmaceuticals (SXTC) China $0.077B 0.00
Novan (NOVN) United States $0.075B 0.00
Pharmaxis (PXSLY) Australia $0.071B 0.00
Neos Therapeutics (NEOS) United States $0.071B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.069B 0.00
SCYNEXIS (SCYX) United States $0.067B 0.00
India Globalization Capital (IGC) United States $0.060B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.059B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.053B 0.00